{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mosquito-Borne+Infectious+Diseases&page=3",
    "query": {
      "condition": "Mosquito-Borne Infectious Diseases",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 109,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mosquito-Borne+Infectious+Diseases&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mosquito-Borne+Infectious+Diseases&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T17:16:57.745Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05095272",
      "title": "Blood-Stage Plasmodium Vivax Cell Bank",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "HMPBS02-Pv",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 2,
      "start_date": "2022-02-15",
      "completion_date": "2022-09-15",
      "has_results": true,
      "last_update_posted_date": "2023-07-11",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05095272"
    },
    {
      "nct_id": "NCT01246479",
      "title": "Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Japanese Encephalitis"
      ],
      "interventions": [
        {
          "name": "Blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "IC51 has given in the parent study IC51-322",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Valneva Austria GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Months",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "9 Months to 20 Years"
      },
      "enrollment_count": 23,
      "start_date": "2010-10",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2020-03-18",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01246479"
    },
    {
      "nct_id": "NCT03776994",
      "title": "Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Encephalitis",
        "Encephalitis, Viral",
        "Infectious Encephalitis",
        "Virus Diseases",
        "Encephalomyelitis, Venezuelan Equine",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Central Nervous System Viral Diseases",
        "Alphavirus Infections",
        "Togaviridae Infections",
        "RNA Virus Infections",
        "Central Nervous System Infections",
        "Encephalomyelitis",
        "Physiological Effects of Drugs",
        "Vaccines",
        "Encephalomyelitis, Equine",
        "Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "Vaccinations on Day 0, Day 28, and Day 140",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "SRI International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2018-07-17",
      "completion_date": "2021-04",
      "has_results": false,
      "last_update_posted_date": "2021-02-23",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 1,
      "location_summary": "Plymouth, Michigan",
      "locations": [
        {
          "city": "Plymouth",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03776994"
    },
    {
      "nct_id": "NCT02061358",
      "title": "Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Infection"
      ],
      "interventions": [
        {
          "name": "UV-4B 3 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 10 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 30 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 90 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 180 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 360 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 720 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 64,
      "start_date": "2014-07",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061358"
    },
    {
      "nct_id": "NCT01489358",
      "title": "Chikungunya Virus Vaccine Trial in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Vaccines",
        "Chikungunya Fever",
        "Chikungunya Virus Infection"
      ],
      "interventions": [
        {
          "name": "VRC-CHKVLP059-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 25,
      "start_date": "2011-12",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-07-25",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489358"
    },
    {
      "nct_id": "NCT04966871",
      "title": "Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "PfSPZ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PfSPZ Challenge (7G8) for CHMI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanaria Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-09-27",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2022-07-18",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04966871"
    },
    {
      "nct_id": "NCT00582504",
      "title": "Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venezuelan Equine Encephalomyelitis"
      ],
      "interventions": [
        {
          "name": "VEE TC-83",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 500,
      "start_date": "2007-09",
      "completion_date": "2022-06",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 1,
      "location_summary": "Fort Deterick, Maryland",
      "locations": [
        {
          "city": "Fort Deterick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582504"
    },
    {
      "nct_id": "NCT03263195",
      "title": "Prospective Cohort Study of HIV and Zika in Infants and Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Zika Virus",
        "Pregnant Women"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Westat",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "15 Years and older · Female only"
      },
      "enrollment_count": 395,
      "start_date": "2017-08-23",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • The Bronx, New York • Houston, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03263195"
    },
    {
      "nct_id": "NCT01335412",
      "title": "Safety Surveillance After Immunization With IXIARO",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Japanese Encephalitis"
      ],
      "interventions": [
        {
          "name": "Japanese Encephalitis Virus vaccine, inactivated, adsorbed",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Valneva Austria GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 20000,
      "start_date": "2011-03",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2015-03-10",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 1,
      "location_summary": "Alexandria, Virginia",
      "locations": [
        {
          "city": "Alexandria",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01335412"
    },
    {
      "nct_id": "NCT00094718",
      "title": "Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "West Nile Fever Encephalitis"
      ],
      "interventions": [
        {
          "name": "WN/DEN4-3'delta30",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2005-02",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-10-23T17:16:57.745Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Nashville, Tennessee",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094718"
    }
  ]
}